Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3271825 | 0.84 | ALDH1A1 (0.45) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL8473914 | 0.83 | CHRM5 (0.41) | CHRM5CHRM3TSHRCYP2D6OPRD1 | |
| SCHEMBL6542505 | 0.83 | MAPT (0.47) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL7306746 | 0.82 | MAPT (0.47) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL12251138 | 0.80 | MGAM (0.36) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL4073904 | 0.79 | CHRM2 (0.38) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL2110264 | 0.77 | SIGMAR1 (0.42) | GAACHRM5CHRM3TSHROPRD1 | |
| SCHEMBL12229557 | 0.77 | CHRM5 (0.41) | CHRM5CHRM3CYP2D6OPRD1OPRM1 | |
| SCHEMBL7016567 | 0.76 | MAPT (0.41) | GAATSHRCYP2D6ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL7970534 | 0.76 | SIGMAR1 (0.41) | GAACHRM5CHRM3TSHROPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906852-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| US-8906852-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| US-20140315801-A1 | METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20140315801-A1 | METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC (CA) | 2014-10-23 | — | — | US | disclosed |
| EP-2563795-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | MethylGene Inc. (CA) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011127567-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011127567-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2011-10-20 | — | — | WO | disclosed |
| US-20110257100-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2011-10-20 | — | — | US | disclosed |
| US-20110257100-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257100-A1 | Inhibitors of Protein Tyrosine Kinase Activity | ERBB2, ABL1, FLT1 | MGAM 3209/4885GAA 762/4885SI 4659/4885 |
| US-20140315801-A1 | METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | FLT1, KDR, FLT4 | MGAM 3730/4885GAA 559/4885SI 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.